- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jason Mitchell Outlines the Role of Commercial Payers in Value-Based Care
Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services, discusses the role of commercial payers in the shift toward value-based care.
Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services, discusses the role of commercial payers in the shift toward value-based care.
Transcript
What role do commercial payers have in the shift toward value-based care?
I think all insurers have a big role in value-based care and commercial is no different than that. If you think about commercial insurance, often times they’re working with large employers, and those employers need healthy populations and they need to have affordable healthcare for their employees because the employees bear the burden of that. So, I think commercial insurers will need to help us push towards more affordable healthcare and delivering on more wellness and health for their populations.
I think you see that also in the Medicare population. Nationally, you’re seeing more and more experimentation with that, and then in the Medicaid population, depending on your state, you’re seeing a lot of experimentation with that, as well. In New Mexico, we’re a Medicaid expansion state, and we’ve been Managed Medicaid for well over 20 years. So, we really work closely with the state to design benefits that really improve the health of the population.
Frameworks for Advancing Health Equity: Youth Behavioral Health Strategy Program
September 17th 2024Chris Barton, LCSW, of Horizon Blue Cross Blue Shield of New Jersey, explores how the Youth Behavioral Health Strategy program focuses on addressing the specific needs of youth with mental health and substance use issues through a comprehensive approach.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
January 13th 2025A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Read More
